Key result
Terazosin linked to ~15 mm Hg standing systolic blood pressure reductions in hypertension.
Why the study?
The long-term safety and efficacy of terazosin, a new selective alpha 1-adrenergic blocking agent, in essential hypertension required evaluation.
Does terazosin reduce blood pressure in patients with essential hypertension?
Population
364 hypertensive patients with essential hypertension
Comparison
Terazosin monotherapy or in combination with other antihypertensive agents
Design
Long-term observational treatment study
Follow-up
3 weeks to 56 months
Authors
Loading...
Terazosin was associated with BP reductions in essential hypertension; leaves open need for randomized confirmation before practice change.
Observational (n=364)
Does terazosin reduce blood pressure in patients with essential hypertension?
Long-term treatment with terazosin effectively and safely reduces blood pressure in patients with essential hypertension without causing significant metabolic adverse effects.
Luther et al. (1988) conducted an observational in Essential Hypertension (n=364). Terazosin was evaluated on Supine and standing systolic and diastolic blood pressures. Terazosin treatment in hypertensive patients produced consistent mean decreases in supine (9-12/10-13 mm Hg) and standing (12-18/11-14 mm Hg) blood pressures.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: